Nasdaq notifies Ensysce of delisting risk for equity shortfall

Ensysce Biosciences, Inc.

Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.
Must submit a plan by July 6, 2026 (45 days) to regain compliance; if accepted, extension up to 180 days from May 21.
Company plans to submit a timely plan and explore options, but no assurance Nasdaq will accept or extension granted.
Failure could lead to delisting; company may appeal to Nasdaq Hearings Panel if plan rejected.

item 3.01

Featured in Daily 8-K Digest

Selected #2 for 2026-05-22. Read digest

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-025061
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2026-05-22T20:55:24+00:00
discovered_at: 2026-05-22T20:56:00.271011+00:00
generated_at: 2026-05-22T20:58:03.305562+00:00
sec_items: ["3.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-025061
json_url: https://secwatch.observer/filing/0001493152-26-025061.json
markdown_url: https://secwatch.observer/filing/0001493152-26-025061.md
text_url: https://secwatch.observer/filing/0001493152-26-025061.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

0e91685b29e13c8ef1e7ef543f0e47eb6853323c

Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

On May 21, 2026, Ensysce Biosciences Inc. (the “ Company ”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of March 31, 2026, the Company is subject to delisting

SEC 8-K Item 3.01 confidence 1.0 SEC evidence

27087ce2350d9925d45f509f7b4401f26ea73cd9

Ensysce Biosciences, Inc. received a nasdaq other notice regarding stockholders equity (rules 5550(b)(1)).

If the plan is accepted, the Company may be granted an extension of up to 180 days from May 21, 2026, to regain compliance.

SEC 8-K Item 3.01 confidence 1.0 SEC evidence

5b8e9c59912ead1eb2b2aa24de4487549bcd80be

Ensysce Biosciences, Inc. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1)).

If the plan is not accepted, the Company may appeal to the Nasdaq Hearings Panel (the “Panel”).

SEC 8-K Item 3.01 confidence 1.0 SEC evidence

7c00c28a878d949f315bb80553f1443ac1392b28

Ensysce Biosciences, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

unless it submits a plan within 45 days (by July 6, 2026) to regain compliance.

SEC 8-K Item 3.01 confidence 1.0 SEC evidence

Source: SEC EDGAR

accession 0001493152-26-025061

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.